SEC Form 4 · accession 0001209191-17-027996
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Troy Edward Wilson
Officer — President and CEO · Director · 10% Owner
Period of report
Apr 21, 2017
Accepted (ET)
Apr 24, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 21, 2017 | M | 5,000 | $4.80 | A | 5,000 | D | |
| Common Stock | holding | — | — | — | 1,735,991 | I | by Red Fish Blue Fish Revocable Trust | |
| Common Stock | holding | — | — | — | 406,736 | I | by Araxes Pharma LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase common stockF1 | $4.80 | Apr 21, 2017 | M | 5,000 | D | — | Jan 28, 2026 | Common stock | 5,000 | 120,000 | D |
Explanation of responses
- F1This option vests in 48 equal monthly installments commencing on 1/29/16.